Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Lantheus Holdings, Inc. (NASDAQ:LNTH). In a filing disclosed on February 11th, the Representative disclosed that they had bought between $1,001 and $15,000 in Lantheus stock on January 7th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.
Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):
- Sold $1,001 - $15,000 in shares of ICF International NASDAQ: ICFI on 2/3/2025.
- Purchased $15,001 - $50,000 in shares of CACI International NYSE: CACI on 1/31/2025.
- Purchased $50,001 - $100,000 in shares of Hawaiian Electric Industries NYSE: HE on 1/31/2025.
- Sold $1,001 - $15,000 in shares of Broadcom NASDAQ: AVGO on 1/30/2025.
- Purchased $1,001 - $15,000 in shares of Intuitive Surgical NASDAQ: ISRG on 1/30/2025.
- Purchased $1,001 - $15,000 in shares of Agios Pharmaceuticals NASDAQ: AGIO on 1/29/2025.
- Purchased $1,001 - $15,000 in shares of SpringWorks Therapeutics NASDAQ: SWTX on 1/29/2025.
- Purchased $1,001 - $15,000 in shares of Paragon 28 NYSE: FNA on 1/29/2025.
- Purchased $1,001 - $15,000 in shares of U.S. Physical Therapy NYSE: USPH on 1/29/2025.
- Purchased $1,001 - $15,000 in shares of Crinetics Pharmaceuticals NASDAQ: CRNX on 1/29/2025.
Lantheus Stock Performance
Lantheus stock traded down $2.02 during mid-day trading on Friday, hitting $79.94. 737,336 shares of the company traded hands, compared to its average volume of 709,331. Lantheus Holdings, Inc. has a one year low of $56.06 and a one year high of $126.89. The stock has a market cap of $5.56 billion, a price-to-earnings ratio of 13.30 and a beta of 0.44. The stock has a fifty day moving average price of $91.43 and a 200-day moving average price of $97.66.
Insider Buying and Selling
In related news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the transaction, the director now directly owns 33,207 shares of the company's stock, valued at $3,146,695.32. The trade was a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.50% of the stock is owned by insiders.
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in LNTH. Wilmington Savings Fund Society FSB purchased a new position in shares of Lantheus during the third quarter worth approximately $25,000. Kestra Investment Management LLC purchased a new position in shares of Lantheus in the fourth quarter worth $27,000. Signaturefd LLC increased its stake in shares of Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock worth $35,000 after buying an additional 92 shares during the period. Summit Securities Group LLC purchased a new position in shares of Lantheus in the fourth quarter worth $37,000. Finally, UMB Bank n.a. increased its stake in shares of Lantheus by 42.1% in the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock worth $47,000 after buying an additional 126 shares during the period. 99.06% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several equities research analysts have issued reports on LNTH shares. JMP Securities reiterated a "market outperform" rating and set a $112.00 target price on shares of Lantheus in a research report on Tuesday, January 14th. StockNews.com lowered shares of Lantheus from a "buy" rating to a "hold" rating in a research report on Thursday, November 21st. The Goldman Sachs Group started coverage on shares of Lantheus in a research report on Wednesday, December 18th. They set a "buy" rating and a $143.00 target price for the company. Finally, Truist Financial reiterated a "buy" rating and set a $120.00 target price (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $131.86.
Get Our Latest Analysis on LNTH
About Representative Cisneros
Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election.
Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.
About Lantheus
(
Get Free Report)
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.
Featured Articles
Before you consider Lantheus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lantheus wasn't on the list.
While Lantheus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
